title: Successful carboplatin desensitization by using omalizumab and paradoxical diminution of total IgE levels.
authors.affiliation: Department of Immunology and Immunopathology, Institute for Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Sydney, Australia.
authors.forename: Samar
authors.initials: S
authors.lastname: Ojaimi
authors.affiliation: Cancer Services, Department of Medical Oncology, Westmead Hospital, Westmead, Sydney, Australia; The Crown Princess Mary Cancer Centre, Westmead, Sydney, Australia.
authors.forename: Paul R
authors.initials: PR
authors.lastname: Harnett
authors.affiliation: Department of Immunology and Immunopathology, Institute for Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Sydney, Australia. Electronic address: david.fulcher@sydney.edu.au.
authors.forename: David A
authors.initials: DA
authors.lastname: Fulcher
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D016190:Carboplatin / Q000009:adverse effects*; D003888:Desensitization, Immunologic / Q000379:methods*; D015536:Down-Regulation; D004342:Drug Hypersensitivity / Q000097:blood / Q000175:diagnosis / Q000276:immunology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood*; D008875:Middle Aged; D000069444:Omalizumab; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D015415:Biomarkers; D000069444:Omalizumab; D007073:Immunoglobulin E; D016190:Carboplatin